The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 5, 2003, Pages 3-17

  Gray, Neil A ^a   Zhou, Rulun ^a   Du, Jing ^a   Moore, Gregory J ^b   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR; LITHIUM; MITOGEN ACTIVATED PROTEIN KINASE; MOOD STABILIZER; NEUROTROPHIN; POLYOMA ENHANCER BINDING PROTEIN 2BETA; PROTEIN BCL 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; BRAIN ATROPHY; BRAIN SIZE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GLIA; GRAY MATTER; HUMAN; MENTAL DISEASE; MOOD DISORDER; NERVE CELL; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPIL; NEUROPROTECTION; NEUROPSYCHIATRIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYNAPSE;

ANTICONVULSANTS; APOPTOSIS; ATROPHY; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; GENE EXPRESSION; GENES, BCL-2; HUMANS; LITHIUM; MENTAL DISORDERS; MOOD DISORDERS; NEURONAL PLASTICITY; NEURONS; SIGNAL TRANSDUCTION; VALPROIC ACID;

EID: 0038643052     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (139)

1. Johnson G. Lithium. Med J Aust 1984;141:595-601
2. Schou M. Bibliography on the biology and pharmacology of lithium: 6. Neuropsychobiology 1979;5:241-265
3. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
4. Vestergaard P, Aagaard J. Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord 1991;21:33-38
5. Muller-Oerlinghausen B, Ahrens B, Grof E, et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand 1992;86:218-222
6. Vestergaard P, Schou M. Lithium treatment in Aarhus, 1: prevalence. Pharmacopsychiatry 1989;22:99-100
7. Heit S, Nemeroff CB. Lithium augmentation of antidepressants in treatmentrefractory depression. J Clin Psychiatry 1998;59(suppl 6):28-33
8. Reifman A, Wyatt RJ. Lithium: a brake in the rising cost of mental illness. Arch Gen Psychiatry 1980;37:385-388
9. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways: molecular targets for lithium's actions. Arch Gen Psychiatry 1995;52:531-543
10. Schou M. Forty years of lithium treatment. Arch Gen Psychiatry 1997;54: 9-13; discussion 14-15
11. Manji HK, Lenox RH. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 2000;48:518-530
12. Mesulam MM. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 1999;24:521-529
13. Manji H, Duman R. Impairments of neuroplasticity and cellular resilience in severe mood disorder: implications for the development of novel therapeutics. Psychopharmacol Bull 2001;35:5-49
14. Manji HK, Drevets WC, Chamey DS. The cellular neurobiology of depression. Nat Med 2001;7:541-547
15. Soares JC, Mann JJ. The functional neuroanatomy of mood disorders. J Psychiatr Res 1997;31:393-432
16. Drevets WC. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 2000;126:413-431
17. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001;11:240-249
18. Strakowski SM, Adler CM, DelBello MP. Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder? Bipolar Disord 2002;4:80-88
19. Beyer JL, Krishnan KR. Volumetric brain imaging findings in mood disorders. Bipolar Disord 2002;4:89-104
20. Lenox RH, Gould TD, Manji HK. Endophenotypes in bipolar disorder. Am J Med Genet 2002;114:391-406
21. Carmelli D, Reed T, DeCarli C. A bivariate genetic analysis of cerebral white matter hyperintensities and cognitive performance in elderly male twins. Neurobiol Aging 2002;23:413-420
22. Taylor WD, Payne ME, Krishnan KR, et al. Evidence of white matter tract disruption in MRI hyperintensities. Biol Psychiatry 2001;50:179-183
23. Stoll AL, Renshaw PF, Yurgelun-Todd DA, et al. Neuroimaging in bipolar disorder: what have we learned? Biol Psychiatry 2000;48:505-517
24. Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord 2002;4: 105-116
25. Bowley M, Drevets W, Ongur D, et al. Low glial numbers in the amygdala and entorhinal cortex in mood disorder. Biol Psychiatry 2002;51:97S-98S
26. Cotter D, Landau S, Beasley C, et al. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry 2002;51:377-386
27. Cotter D, Mackay D, Chana G, et al. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002;12:386-394
28. Miguel-Hidalgo J, Rajkowska G. Reduction of glia in the prefrontal cortex: a hypothesis of its role in the pathophysiology of major depressive disorder [abstract]. Biol Psychiatry 2002;51:98S
29. Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 2001;55: 585-595
30. Coyle JT, Schwarcz R. Mind glue: implications of glial cell biology for psychiatry. Arch Gen Psychiatry 2000;57:90-93
31. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998;95:13290-13295
32. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999;45:1085-1098
33. Ullian EM, Sapperstein SK, Christopherson KS, et al. Control of synapse number by glia. Science 2001;291:657-661
34. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996; 153:151-162
35. Wang JF, Young LT. Differential display PCR reveals increased expression of 2′,3′-cyclic nucleotide 3′-phosphodiesterase by lithium. FEBS Lett 1996;386: 225-229
36. Lenox RH, McNamara RK, Papke RL, et al. Neurobiology of lithium: an update. J Clin Psychiatry 1998;59(suppl 6):37-47
37. Jope RS, Song L. AP-1 and NF-kappaB stimulated by carbachol in human neuroblastoma SH-SY5Y cells are differentially sensitive to inhibition by lithium. Brain Res Mol Brain Res 1997;50:171-180
38. Ozaki N, Chuang DM. Lithium increases transcription factor binding toAP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem 1997;69:2336-2344
39. Asghari V, Wang JF, Reiach JS, et al. Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res 1998;58:95-102
40. Chen G, Yuan PX, Jiang YM, et al. Valproate robustly enhances AP-1 mediated gene expression. Brain Res Mol Brain Res 1999;64:52-58
41. Ikonomov OC, Manji HK. Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. Am J Psychiatry 1999;156:1506-1514
42. Chen G, Zeng WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999;72:879-882
43. Manji HK, Moore GJ, Chen G. Lithium up-regulates the cytoprotective protein bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 2000;61(suppl 9):82-96
44. Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 1999;46: 929-940
45. Chen G, Rajkowska G, Du F, et al. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000;75:1729-1734
46. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression: a prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999;274:6039-6042
47. Lu R, Song L, Jope RS. Lithium attenuates p53 levels in human neuroblastoma SH-SY5Y cells. Neuroreport 1999;10:1123-1125
48. Merry DE, Korsmeyer SJ. Bcl-2 gene family in the nervous system. Annu Rev Neurosci 1997;20:245-267
49. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-1326
50. Bruckheimer EM, Cho SH, Sarkiss M, et al. The Bcl-2 gene family and apoptosis. Adv Biochem Eng Biotechnol 1998;62:75-105
51. Gorman AM, Ceccatelli S, Orrenius S. Role of mitochondria in neuronal apoptosis. Dev Neurosci 2000;22:348-358
52. Chen DF, Tonegawa S. Why do mature CNS neurons of mammals fail to reestablish connections following injury? functions of bcl-2. Cell Death Differ 1998;5:816-822
53. Holm KH, Cicchetti F, Bjorklund L, et al. Enhanced axonal growth from fetal human bcl-2 transgenic mouse dopamine neurons transplanted to the adult rat striatum. Neuroscience 2001;104:397-405
54. Chierzi S, Strettoi E, Cenni MC, et al. Optic nerve crush: axonal responses in wild-type and bcl-2 transgenic mice. J Neurosci 1999;19:8367-8376
55. DeVries AC, Joh HD, Bernard O, et al. Social stress exacerbates stroke outcome by suppressing Bcl-2 expression. Proc Natl Acad Sci U S A 2001;98: 11824-11828
56. Watson SJ, Akil H. Gene chips and arrays revealed: a primer on their power and their uses. Biol Psychiatry 1999;45:533-543
57. Nadon R, Shoemaker J. Statistical issues with microarrays: processing and analysis. Trends Genet 2002;18:265-271
58. Yang F, Li X, Sharma M, et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002;277:11336-11344
59. Liang P. A decade of differential display. Biotechniques 2002;33:338-344, 346
60. Lee ML, Kuo FC, Whitmore GA, et al. Importance of replication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations. Proc Natl Acad Sci U S A 2000;97:9834-9839
61. Alizadeh AA, Ross DT, Perou CM, et al. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 2001;195: 41-52
62. Yuan PX, Huang LD, Jiang YM, et al. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001;276:31674-31683
63. Chen G, Huang LD, Jiang YM, et al. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999;72: 1327-1330
64. Yuan PX, Chen G, Huang LD, et al. Lithium stimulates gene expression through the AP-1 transcription factor pathway. Brain Res Mol Brain Res 1998;58:225-230
65. Tseng GC, Oh MK, Rohlin L, et al. Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects. Nucleic Acids Res 2001;29:2549-2557
66. Hall AC, Brennan A, Goold RG, et al. Valproate regulates GSK-3-mediated axonal remodeling and synapsin 1 clustering in developing neurons. Mol Cell Neurosci 2002;20:257-270
67. Hall AC, Lucas FR, Salinas PC. Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell 2000;100: 525-535
68. Lucas FR, Salinas PC. WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons. Dev Biol 1997;192:31-44
69. Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001; 2:24-32
70. Fryer RH, Kaplan DR, Feinstein SC, et al. Developmental and mature expression of full-length and truncated TrkB receptors in the rat forebrain. J Comp Neurol 1996;374:21-40
71. Gonzalez M, Ruggiero FP, Chang Q, et al. Disruption of Trkb-mediated signaling induces disassembly of postsynaptic receptor clusters at neuromuscular junctions. Neuron 1999;24:567-583
72. Mamounas LA, Blue ME, Siuciak JA, et al. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 1995;15:7929-7939
73. Goggi J, Pullar IA, Carney SL, et al. Modulation of neurotransmitter release induced by brain-derived neurotrophic factor in rat brain striatal slices in vitro. Brain Res 2002;941:34-42
74. Schinder AF, Berninger B, Poo M. Postsynaptic target specificity of neurotrophin-induced presynaptic potentiation. Neuron 2000;25:151-163
75. Drake CT, Milner TA, Patterson SL. Ultrastructural localization of full-length trkB immunoreactivity in rat hippocampus suggests multiple roles in modulating activity-dependent synaptic plasticity. J Neurosci 1999;19: 8009-8026
76. Riccio A, Ahn S, Davenport CM, et al. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science 1999;286:2358-2361
77. Bonni A, Brunet A, West AE, et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999;286:1358-1362
78. Chen G, Einat H, Yuan P, et al. Evidence for the involvement of the MAPK/ERK signaling pathway in mood modulation [abstract]. Biol Psychiatry 2002;51:368s
79. Haugaard ES, Mickel RA, Haugaard N. Actions of lithium ions and insulin on glucose utilization, glycogen synthesis and glycogen synthase in the isolated rat diaphragm. Biochem Pharmacol 1974;23:1675-1685
80. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996;93:8455-8459
81. Woodgett JR. Judging a protein by more than its name: GSK-3. Sci STKE 2001;2001:RE12
82. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001;280: 720-725
83. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001;41:789-813
84. Gould TD, Manji HK. The Wnt signaling pathway in bipolar disorder. Neuroscientist 2002;8:497-511
85. Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 2002;4:137-144
86. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000;48: 740-754
87. Lucas FR, Goold RG, Gordon-Weeks PR, et al. Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J Cell Sci 1998;111:1351-1361
88. Hilfiker S, Pieribone VA, Czernik AJ, et al. Synapsins as regulators of neurotransmitter release. Philos Trans R Soc Lond B Biol Sci 1999;354: 269-279
89. Kao HT, Song HJ, Porton B, et al. A protein kinase A-dependent molecular switch in synapsins regulates neurite outgrowth. Nat Neurosci 2002;5: 431-437
90. Takashima A, Noguchi K, Sato K, et al. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A 1993;90:7789-7793
91. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1998; 273:19929-19932
92. Crowder RJ, Freeman RS. Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J Biol Chem 2000;275:34266-34271
93. Hetman M, Cavanaugh JE, Kimelman D, et al. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci 2000;20:2567-2574
94. Culbert AA, Brown MJ, Frame S, et al. GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity. FEBS Lett 2001;507:288-294
95. Martinek S, Inonog S, Manoukian AS, et al. A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 2001; 105:769-779
96. Klemfuss H. Rhythms and the pharmacology of lithium. Pharmacol Ther 1992;56:53-78
97. Wager-Smith K, Kay SA. Circadian rhythm genetics: from flies to mice to humans. Nat Genet 2000;26:23-27
98. Reppert SM, Weaver DR. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol 2001;63:647-676
99. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769-776
100. Maccioni RB, Munoz JP, Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 2001;32: 367-381
101. Volonte C, Rukenstein A. Lithium chloride promotes short-term survival of PC12 cells after serum and NGF-deprivation. Lithium 1993;4:211-219
102. D'Mello SR, Anelli R, Calissano P. Lithium induces apoptosis in immature cerebellar granule cells but promotes survival of mature neurons. Exp Cell Res 1994;211:332-338
103. Li R, Shen Y, El-Mallahk RS. Lithium protects against ouabain-induced cell death. Lithium 1994;5:211-216
104. Alvarez G, Munoz-Montano JR, Satrustegui J, et al. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett 1999;453:260-264
105. Inouye M, Yamamura H, Nakano A. Lithium delays the radiation-induced apoptotic process in external granule cells of mouse cerebellum. J Radiat Res (Tokyo) 1995;36:203-208
106. Pascual T, Gonzalez JL. A protective effect of lithium on rat behaviour altered by ibotenic acid lesions of the basal forebrain cholinergic system. Brain Res 1995;695:289-292
107. + protection of cerebellar granule neurons switched to non-depolarizing medium. Eur J Pharmacol 1996;315:111-114
108. Chuang DM, Chen RW, Chalecka-Franaszek E, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002;4:129-136
109. Bijur GN, De Sarno P, Jope RS. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis: protection by lithium. J Biol Chem 2000;275:7583-7590
110. Arendt T, Lehmann K, Seeger G, et al. Synergistic effects of tetrahydroaminoacridine and lithium on cholinergic function after excitotoxic basal forebrain lesions in rat. Pharmacopsychiatry 1999;32:242-247
111. Sparapani M, Virgili M, Ortali F. et al. Effects of chronic lithium treatment on ornithine decarboxylase induction and excitotoxic neuropathology in the rat. Brain Res 1997;765:164-168
112. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998;9:2081-2084
113. Wei H, Qin ZH, Senatorov VV, et al. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 2001;106:603-612
114. Chen G, Hasanat KA, Bebchuk JM, et al. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med 1999;61:599-617
115. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 1999;96:8745-8750
116. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241
117. Kempermann G, Gage FH. Experience-dependent regulation of adult hippocampal neurogenesis: effects of long-term stimulation and stimulus withdrawal. Hippocampus 1999;9:321-332
118. Chen DF, Schneider GE, Martinou JC, et al. Bcl-2 promotes regeneration of severed axons in mammalian CNS. Nature 1997;385:434-439
119. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000;48:813-829
120. Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 1995;46:531-540
121. Moore GJ, Bebchuk JM, Hasanat K, et al. Lithium increases N-acetylaspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 2000;48:1-8
122. Moore GJ, Bebchuk JM, Wilds IB, et al. Lithium-induced increase in human brain grey matter. Lancet 2000;356:1241-1242
123. Moore G, Rajarethinam R, Cortese B, et al. Regionally specific increases in human brain gray matter with chronic lithium treatment [abstract]. Presented at the 31st annual meeting of the Society for Neuroscience; Nov 11, 2001; San Diego, Calif
124. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 1998;95:2642-2647
125. Ren M, Chen RW, Senatorov VV, et al. Acute lithium protects against brain injury in an ischemia/reperfusion model of rats [abstract]. Presented at the 30th annual meeting of the Society for Neuroscience; Nov 6, 2000; New Orleans, La
126. Hashimoto R, Hough C, Nakazawa T, et al. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002;80:589-597
127. Perlis RH, Sachs GS, Lafer B, et al. Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am J Psychiatry 2002; 159:1155-1159
128. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989;321:1489-1493
129. Waters B, Lapierre Y, Gagnon A, et al. Determination of the optimal concentration of lithium for the prophylaxis of manic-depressive disorder. Biol Psychiatry 1982; 17:1323-1329
130. Abou-Saleh MT, Coppen A. The efficacy of low-dose lithium: clinical, psychological and biological correlates. J Psychiatr Res 1989;23:157-162
131. Coppen A, Abou-Saleh MT. Lithium therapy: from clinical trials to practical management. Acta Psychiatr Scand 1988;78:754-762
132. Prien RF, Caffey EM Jr. Relationship between dosage and response to lithium prophylaxis in recurrent depression. Am J Psychiatry 1976;133: 567-570
133. Rouillon F. Gorwood P. The use of lithium to augment antidepressant medication. J Clin Psychiatry 1998;59(suppl 5):32-39
134. de Montigny C, Cournoyer G, Morissette R, et al. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. Arch Gen Psychiatry 1983;40: 1327-1334
135. Wilkinson D, Holmes C, Woolford J, et al. Prophylactic therapy with lithium in elderly patients with unipolar major depression. Int J Geriatr Psychiatry 2002;17:619-622
136. Sheline YI, Sanghavi M, Mintun MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999;19:5034-5043
137. Strakowski SM, Wilson DR, Tohen M, et al. Structural brain abnormalities in first-episode mania. Biol Psychiatry 1993;33:602-609
138. Hirayasu Y, Shenton ME, Salisbury DF, et al. Subgenual cingulate cortex volume in first-episode psychosis. Am J Psychiatry 1999;156:1091-1093
139. Manji HK, Quiroz JA, Sporn J, et al. Enhancing synaptic plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. In press